Brigham and Women's Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Brigham and Women's Hospital sits in the top decile of US sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count).
Brigham and Women's Hospital: 937 sponsored US clinical trials, 145 recruiting.
Brigham and Women's Hospital sponsors 937 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 608 completed. 124 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes, with 13 trials.
Top-decile sponsor footprint
Brigham and Women's Hospital ranks in the top decile of sponsors by registered trial count (#35 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
608 of 677 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
937 total, page 18 of 19
Metabolomic Profiling of Novel Mediators of Vascular Function
NCT00762242
REVEAL III: Risk Evaluation and Education for Alzheimer's Disease
NCT00462917
Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital
NCT00550264
MDMA-assisted Therapy in People With Anxiety Related to Advanced Stage Cancer
NCT00252174
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
NCT00401414
Prospective Study of Dietary Factors, BMI, and Risk of Asthma in Children
NCT00454415
UVB Phototherapy Treatment of Oral Chronic GVHD
NCT00374257
The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
NCT00366301
Heparin Induced Thrombocytopenia: Pharmacoeconomics
NCT00456001
Treatment of Hypochondriasis With CBT and/or SSRI
NCT00339079
Study of Perfusion and Anatomy's Role in Coronary Artery (CAD)
NCT00321399
Implementation and Evaluation of a Medical Reconciliation Protocol at Brigham and Women's Hospital
NCT00296426
Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
NCT00413374
Treatment of Refractory Status Epilepticus
NCT00265616
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
NCT00759291
Epidemiology of Venous Thromboembolism
NCT00456196
Endothelial Function in Lower Extremity Bypass Grafts
NCT00759707
Computer-Based Stop Smoking Program in Assisting Doctors in Helping Adults Stop Smoking
NCT00383461
Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
NCT00413309
Interaction of Chronic Sleep Restriction and Circadian Misalignment on Sleep and Neuro-cognitive Performance
NCT00438438
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
NCT00413504
A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
NCT00323635
Multi-Center Human Alert Trial to Prevent DVT and PE
NCT00409136
The Bar Coded Sponge Study
NCT00282750
Sleep Loss and Mechanisms of Impaired Glucose Metabolism
NCT00555750
A Pilot Study of Etanercept in Dermatomyositis
NCT00112385
Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia
NCT00303342
Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty
NCT00289601
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
NCT00319982
Randomized Controlled Trial of Dexmedetomidine for the Treatment of Intensive Care Unit (ICU) Delirium
NCT00351299
Improving the Outpatient Referral Process With Electronic Communications
NCT00129064
Comprehensive Police Fatigue Management Program
NCT00246051
Examining the Biological Factors That Affect Sleep Duration
NCT00607204
Melatonin Supplements for Improving Sleep in Individuals With Hypertension
NCT00238108
Heparin-Induced Thrombocytopenia Registry
NCT00456326
Stress, Environment, and Genetics in Urban Children With Asthma
NCT00269256
Free Fatty Acids and Vascular Function in Subjects With Diabetes
NCT00153179
KEEPS Mammographic Density And Breast Health Ancillary Study
NCT02524561
Inflammation and Vascular Function in Atherosclerosis
NCT00760019
Thyroid Hormone Dose Adjustment in Pregnancy
NCT00230802
The Effects of Atorvastatin in Patients With Atherosclerosis
NCT00115817
Sleep Disorders Management, Health and Safety in Police
NCT00207285
Integrated Treatment Program for Hypochondriasis in Primary Care Settings
NCT00368212
Effects of Vitamin B12 on the Body's Internal Clock
NCT00120484
Using Barcode Technology to Improve Medication Safety
NCT00243373
Effects of Different Colors of Light on Human Physiology
NCT00200863
Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial
NCT00207259
Dietary Salt Intake and Vascular Function
NCT00590512
Characterization of Placebo Responses in Stable Asthma
NCT01143688
Women's Health Habits Study
NCT00846638
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 90 |
| Phase 2 | 107 |
| Phase 3 | 47 |
| Phase 4 | 77 |
Therapeutic Areas
What is open in the Brigham and Women's Hospital pipeline
145 recruiting of 937 indexed (15% open); 608 completed (65%).
Phase mix: 124 late (III/IV) vs 197 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Brigham and Women's Hospital: open-pipeline peers nationwide
Peers matched on 937 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Brigham and Women's Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 937 trials (± recruiting share)
- Columbia University · 958 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- University of Minnesota · 966 trials · 19% recruiting
- University of California, Los Angeles · 897 trials · 18% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Incyte Corporation · 15% recruiting · 239 trials
- Northwestern University · 15% recruiting · 1,209 trials
- Nationwide Children's Hospital · 15% recruiting · 188 trials
- University of Michigan Rogel Cancer Center · 15% recruiting · 292 trials
Related
What to do with this Brigham and Women's Hospital page
937 registered trials is a research-attention snapshot, not an endorsement of Brigham and Women's Hospital or any single study.
- 145 of Brigham and Women's Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes is the condition Brigham and Women's Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Brigham and Women's Hospital pipeline card: 937 registered trials from official public datasets.Report a data error.